
ADCs and PARP Inhibitors Are Among 2025’s Practice-Changing Agents in Ovarian Cancer
Since the December 2014 FDA approval of the PARP inhibitor olaparib (Lynparza) for the treatment of patients with BRCA-mutant advanced ovarian cancer, the respective treatment landscape has seen immense developments, from targeted therapies like PARP …